ISI WILY ONLINE LIBRARY ISC
27
/ - . . . . . - [email protected] . . . . . . . . " : WILY ONLINE LIBRARY ISI web of sceince Link Springer Sciencedirect Pubmed google scholar SID ISC ) ( . ) . . : - . / / / / / / Multipotent Selfrenewal Downloaded from sjku.muk.ac.ir at 23:18 +0330 on Sunday October 17th 2021 [ DOI: 10.22102/20.3.113 ]
Transcript of ISI WILY ONLINE LIBRARY ISC
/-
.
.
.
.
.
-
.
.
.
.
..
..
"
:
WILY ONLINE LIBRARYISI
web of sceinceLink SpringerSciencedirect Pubmed google scholarSIDISC
)
(.
)
.
.
:
-
.
//////
Multipotent
Selfrenewal
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
)(.
)(
Long Term
Subtype
Enner Cell Mass
Induced Pluripotent Stem Cells(iPS)
Embryonic Stem Cells(ESCs)
MSCs
Colony Forming Unite-Fibroblast
Invitro
)(
---
CXCR4
) -(
)(.
)(.
Mobolized
Cell-Cell Contact
Feeder
Stromal Derived Factor-1
Invivo
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
.
WILY ONLINE LIBRARY
ISI web of sceince
Link SpringerSciencedirect Pubmed google scholar
SIDISC
:
-
-
.
Mesenchymal Stem Cell Transplantation
Immunomodulation
Cell Therapy
Regenerative Medicine
Tissue Engineering
Cell-Cell Contact
Tropic Factors
Simmon
STOR1
STOR1+CFU-F
)(
)(
CD13CD24CD44CD54CD73CD105
CD166CD90 MHC-IVCAM/CD106
MCAM/CD146
CD11b CD34CD45CD14CD19
(HLA-DR) MHC-IICD79aCD31
( )(.
)( .
Colony Forming Unite-Fibroblast
Fibroblast
Like Cells
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
.
MSCs )(
.
)-(.
)(
Runx2
Twist 2
PPAR 2
SOX9
)(.
Wharton-jelly
MHC-II
)(
CD45
)(
: -
:
SSEA-3SSEA-4
TRA(1-60)TRA(1-81)
CD9CD29CD4
CD49dCD49eCD49f
CD45
Amniotic Membrane Endothelial Cells(AMECs)
Stage
Specific Embryonic Ag
Tumor Rejection Ag
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
)(
-
CFU-F
CD29
CD44CD49dCD49eCD56CD73
CD90CD105CD166
.
)( .
GVHD
)(
HLA
)( .
)(
)(
)(.
Amniotic Membrane MSCs(AM-MSCs)
)(
B
)(.
)(
TSG-6
)(.
cDNA
Tumor Necrosis Factor-inducible gene 6 protein
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
Oct-4Sox-2NanogRex-1
)( .
T
)(
)(.
MHC
T
Fas/FasL
T
MHC-I
MHC-IIFasL
B7-1B7-2CD40CD40L
)(
ICAM1
)(
)(
TLR 2,3,4,7,9
TLR
Pluripotent
Antigen Processing Machinary
Intracellular Cell Adhesion Molecule
IFN-
Toll-Like receptors
)(
TB
)(
ILTR-2,3,4
)(
.
T
PGE-2 TGF-HGF
HLA-GIDO
)-
IDOPGE-2
-
(CD4+ CD8+
IL-10
IFN-
IL-2IL-15
B
)(.
HLAG
Programmed Cell Death Receptor-1,2
Immunoglobulin Like Transcript Receptor 2,3,4
Upregulation
Inducible Nitic Oxid
Indoleamine 2,3 Dioxygenase
Resting NK Cells
Downregulation
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
B7-H1 B7-H4
)-
(.
HLA-G
T
)(.
HLA-G
HLA
)( .
B
CD4+
CD8+T
NKT
Immune Privileged Organs
Pleotropic
)(
B7-H2 MHC-II
)(
CCR1
CCR2CCR4CCR7CXCR5CCR10
)(
IL-6LIF
SCF Ang1Jagged 1
IL-10 TGF-VEGF
HLA-GIDO
NOE
(.
TTh1Th2
TNF-IL-1IFN-
IL-10
)(.
Leukemia Inhibitory Factor
Stem Cell Factor
soluble HLA-G
Hepatocyte Growth Factor
T naive
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
.
Magatti
-
CCL2CCL8IL-6
TNF-CXCL10
CCL5
.
)(.
TB
NO
IDOPGE2
TSG6
CCL2 PD1
TNF-
IFN-IL-1
)( .
Dendretic Cells (
Soluble Factors Function
IDO Inhibition of Proliferation
NO Inhibition of Tryptophan
Inhibition of Proliferation , Cytotoxicity HGF
sHLA-G,TGF- Inhibition of Proliferation , Cytotoxicity
Promotion of Treg Generation
PGE-2 Inhibition of Proliferation , Cytotoxicity
Stimulation of Cell Activation and Inhibition of DC and Treg Stimulation
IFN- ,TNF- ,IL-1 Promotes Chemokine Production and Immunosuppressive Factor Such as NO or IDO
IL-6 Regulates Migration , Stimulates Mitosis and Angiogenesis
IL-10 Inhibition of Apoptosis
VEGF Inhibition of Apoptosis , Stimulates Angiogenesis
LIF Inhibition of Apoptosis
SCF Supports Growth and Differentiation
Jagged-1 Enhances Differentiation
CCLs&CXCLs Promotes Migration of Leukocytes
D
ownl
oade
d fr
om s
jku.
muk
.ac.
ir at
23:
18 +
0330
on
Sun
day
Oct
ober
17t
h 20
21
[ D
OI:
10.2
2102
/20.
3.11
3 ]
)(
T
MHC-I,II
CD11c
CD83
)(+ CD14
CD34+
CD40
CD80CD83CD86
)(CD1a
)(PGE-2
CD80CD83CD86IL-
12
)-
(.
IL-12TNF-IL-1
IL-10
MHC-II
MHC-II
IL-10(
)(
HLA-G
T
Co-stimulatory molecules
T
)(.
NK Cells(
TGF-sHLA-G PGE-2
-
IL-2
Krampera
HLA-I
.
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
)(.
NK
)(. RT-
PCR ELISA
)(.
T
T
TCD8+ (
.
T
MLR
)(.
SessaregoT
TCR CD28
)( . Roelen
MLR
IL-2
IL-4IL-7IL-10IL-15IFN-MLR
MLR
Kang
T Cell Receptor(TCR)
Mixed Lymphocyte Reaction
Vascular Endothelial Growth Factor(VEGF)
IL-17 IFN-
).(
IL-10 TGF-
mRNA TGF-HGFIDO-
TranswellIL-10
TGF-
MLR
)(.
IL-10
T
)(.
CD4+CD8+
T CD4+CD8+
Transwell T CD4+CD8+
)( .Li
IL-10
Th2IL-2IFN-
Th1
T Th1
Th2
)(.
IL-10
Treg CD4+CD25+highFoxp3+
Cyclooxygenase-2(COX-2)
Maternal
Phytohemagglutinine(PHA)
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
)(. T
PHA.
Li
T
Fas/Fas-L :
T
:
-
)(.
TT
T
CD3CD28
T
T
CD3
CD28
)(
CD25CD38
CD69
T CD4+CD8+
T
G0/G1
D2
T.
. )(
CCL1sHLA-G
TTh2
T
)(.
PGE-2IDOTGF-
T
CD4+
CD25+ Foxp3TCD8+
TCD4
PGE-2
TGF-
T
HLA-G
B7-H4
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
T
T
)(
HLA-G
B7-H4
)(
B
T
BIFN-
B )
)(
B
B
)(.
I-III Singer
)(.
MSCs )(
-
(
GVHD
)
-
Graft Versus Host Disease
GVHD
)(.
)(
GVHD
)(
)(.
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
MHC
)(
)(.
-
)(
-
)(.
)-(.
MMP
Systemic Administration
Myocardial Infaction(IM)
Matrix Metalloprotienase
)(C-X-C
Motif
C-X-C Motif
C-C MotifC-C
Motif
CXCR4
MI
)(. P-Selectin
VCAM-1 VLA-4
VCAM-1
)-
(.
MMPMMP-2MMP -
TNFIL-1
)(.
TLR
VEGF
KGF
PDGFIGF1
bFGFHGFIL-6CCL2
)(
Transduce
Coat
Inflammatory Bowel Disease(IBD)
Membrane Type-1-MMP
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
MI
)(.
T
BT
)(.
IL-10
PGE-2
)(
GVHD-
()( .
Gene Modification
T
)(
)(.
AMS
)(
)(.
n =()(
IFN-
IL-17
)CNS(
)(
Systemic Lupos Erythmatosis(SLE)
Crohn's Disease
Atrophy Multiple System
Strock
Administration
Score
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
IGF-1
VEGFEGFbFGF
IL-10
TNF-
.
AKT
)(.
Xenotransplantation
Infarct
Neurotrophic Factor(BDNF) Brain-Derived
Nerve Growth Factor(NGF)
Axotomized
Locomotion
F4/80
)(
:
-
)(.
Hemisected
Penumbra
Nissel
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
)(.
:
T
)(.
MS
McDonald
MS
T
Li
TCD3
F4/80(+)
TGF-
PGE-2
Th2
IL-5
)(.
:
EAE )Experimental Autoimmune Encephalomyelitis(
.
Homebox1
Nude
Streptozotocin
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
)(
)
(
Mansouri et al.(
CCL4
TGF- 1
CCL4T
CCL4
T
MCP-1
CCL4
M2YM-1IL-10
CD206
Xenotransplantation
Monocyte Chemoattractant Protien-1
Rosolution
)(.
GVHD:
GVHD
GVHD
Prochymal
GVHD )II-IV(%
Prochymal
%(
Prochymal
Prochymal
)(. Sudres
GVHD
GVHD
Sudres -
GVHD
-
)(.
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
:
TNF-IFN-
MCP-1IL-6
IL-10
)(.
IL-10TGF-
IL-10 IL-4
Treg
HGF
IgE
)(.
BMP-2
.
Transfer
Hydroxyapatite tricalcium Phosphate
.
)(.
VEGF
IGF-1AdernomedulinHGF
-
.
)(.
)(
Load
Segmental
Cardioprotectin
Rate
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
IFN-IFN-
IL-12 TNF
)-(
.
)(Dongmei Zhang
Endostatin
)Ad-EndoCPC
)(.
)(.
Primary or Denevo
TRAIL
Transduct
Peritoneal Carcinomatosis Colorectal
)(.
)
.
GVHD
-
.
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
MHCI,II
)(.
GVHD
Sudres
GVHD
GVHD
)(.
Dongmei
)(.
)(. Lu
P21
G0/G1
)(.
)(
MR Moniri
.
.
)AktWntNFkB(
.
. Ning
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
Bernardo
GVHD
Carrion
SLE
SLELiang
Sun
)(.
GaoJ
FISHY
PCRHLA
)(.
Liu
/
/
)(Yanes
)ADSC(
/
)( .
Transwell
Flurescent In Situ Hypridization
Polymerase Chain Reaction
Human Leukocyte Antigen
Antibody-Dependent Cell-Mediated Cytotoxicity
)BM-MSC( .
LiTranswell
)( .Kampera
BM-MSCs
T
)APCs(
)(Augella
PD1,2
T
B
)(.
-
)Safety(:
. Shihua Wang
IL-6
Th17.
:
Vaibility
-
:
Rubio D
Clinical Grade Production
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
-
.
c-myc
.
Bernardo
-
MHC-I
MHC-II
CD80,CD86CD40
.
-
)(.
Immune Privileged
.
.
.
D
ownl
oade
d fr
om s
jku.
muk
.ac.
ir at
23:
18 +
0330
on
Sun
day
Oct
ober
17t
h 20
21
[ D
OI:
10.2
2102
/20.
3.11
3 ]
References 1. Biabco P, Robey PG, Simmons Pj. Mesenchyal Stem Cells:Revisiting History,concepts, and assays.Cell Stem Cell 2008;2:313-319. 2. Xin WEI , XUe YANG ,Zhi peng HAN,Fang-fang Qu,Li Shao and Yu-fang Shi. Mesenchymal stem cells: a new trend for cell therapy.Acta Pharmacologia Sinica 2013;34:747-754. 3. Oubari F, Amirizadeh N, Mohammadpour H, Nakhlestani M, Nikougoftar Zarif M. The important role of Flt3-l in exvivo expansion of hematopoietic stem cells following co-culture with mesenchymal stem cells. Cell Journal 2015;17. 4. Oubari F, Nikougoftar Zarif M, Amirizadeh N,Shaiegan M,Atarodi A,Nakhlestani et al.Isolation and expansion of Mesenchymal Stem cells from placenta. Sci J Iran Blood Transfus Organ 2013; 10: 222-230.
5. Amit N Patel, Jorge Genovese. Potential clinical application of adult human mesenchymal stem cell (Prochymal) therapy.Stem Cell Cloning: Advances and Applications 2011:4, 61-72. 6. Gebler A, Zabel O, Seligar B. The immunomodulatory capacity of Mesenchymal stem cells. Trends Mol Med 2012;2:128-34. 7. Nayoun Kim and Seok-Goocho. Clinical application of mesenchymal stem cells.Korean J Intern Med 2013 ;28:387-402. 8. In t Anker PS, Scherjon SA,Kleijburg-van der Keur C , de Groot-Swing GM , Class FH , Fibbe WE, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004;22:1338-45. 9. Ulrich C, Rolauffs B, Abele H,Bonin M , Nieselt K , Hart ML, et al. Low osteogenic differentiation potential of placenta-derived mesenchymal stromal cells correlates with low expression of the transcription factors Runx2 and Twist2. Stem Cells Dev 2013;22:2859-72. 10. Carmen L Insausti , Blanquer M , Ana M, Castellanos G and Moraleda JMet al.Amniotic membrane derived stem cells: immunomodulatory properties and potential clinical application. Stem Cells Cloning 2014;7 :53-63. 11. Shihua Wang , Xuebin Qu and Robert Chunhua Zhao.Clinical application of mesenchymal stem cells. Journal of hematology &onchology 2012; 5:19. 12. Tzaribachev N, Vaegler M, Schaefer J, Reize P, Rudert M, Handgretinger R , et al. Mesenchymal stromal cells:a novel treatment option for steroid induced avascular osteonecrosis.Isr Med Assoc J 2008;10:232-4. 13. Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F ,Aqhajani K ,Jafari F, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection:a phase I-II clinical trial . Eur J Gastroenterol Hepatol 2009; 21:1199-205. 14. Lu D , Chen B , Liang Z , Deng W,Jiang Y , Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow
derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double
blind , randomixed , controlled trial . Diabetes Res Clin Pract 2011; 92:26-36. 15. Rasulov MF, Vasilchenko AV, Onishchenko NA,Krasheninnikov ME, Kravchenko VI, Gorshenin TL, et al . First experience of the use bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns. Bull Exp Biol Med 2005;139:141-4. 16. Dai Lj, Moniri MR, Zheng ZR,Zhou JX, Rayat J , Warnock GL. Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett 2011 ;305:8-20. 17. Smith H, Whittall C, Weksler B, Middleton JFS . Chemkines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev 2012 ;21:476-486.
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
18. Parolini O, Alviano F, Bagnara GP, Bilic G, Magatti M, Buhring HJ, et al. Concise review :isolation and characterization of cells from human term placenta: outcome of the first international Workshop on placenta Derived
derived Stem Cells. Stem Cells 2008 ;26:300-
311. 19. Ivanova Todorova E, Mourdjeva M, Kyurkchiev D, Bochev I, Stoyanova E , Dimitrov R , et al. HLA-G expression is up regulated by progesterone in mesenchymal stem cells.Am J Reprod Immunol 2009 ;62:25-33. 20. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E , Ringden O.HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.Exp Hematol 2003;31:890-6. 21. IIancheran S, Moodley Y, Manuelpillai U. Human fetal membranes: a source of stem cells for tissue regeneration and repair? Placenta 2009 ; 30:2-10. 22. MiKi T, Strom SC. Amnion
Derived Pluripotent /Multipotent Stem Cells. Stem Cells Rev 2006; 2:133-42. 23. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by Mesenchymal Stem Cells : A Potential Therapeutic Strategy for Type I Diabetes. Diabetes 2008; 57:1759-67. 24. Sotiropoulou PA, Perez SA,Gritzapis AD, Baxevanis CN, Papamichail M.Interaction Between Human Mesenchymal Stem Cells and Natural Killer Cells. Stem Cells 2006 ; 24:74-85. 25. Magatti M , De Munari S, Vertua E, Nassauto C , Albertini A , Wengler GS, et al.Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant 2009;18:899-914. 26. Magatti M , De Munari S , Vertua E, Gibelli L , Wengler GS , Parolini O .Human amnion mesenchyme harbors cells with allogeneic T- cell suppression and stimulation capabilities.Stem Cells 2008; 26:182-92. 27. Roelen DL,van der Mast BJ, int Anker PS, Kleijburg C, Eikmans M , Beelen Ev, et al. Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol 2009; 70:16-23. 28. Li C, Zhang W, Jiang X, Mao N.Human placenta
derived mesenchymal stem cells inhibit proliferation and function of allogenic immune cells. Cell Tissue Res 2007; 330:437-46. 29. Macotonia SE, Hosken NA, Litton M, Vieira P , Hsieh CS , Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ Tcells.J Immunol 1995;154:5071-9. 30. Chen PM, Yen ML, Liu Kj, Sytwu HK, Yen BL. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells.J Biomed Sci 2011;18:49. 31. Sivanathan KN, Gronthos S , Rojas-Canales D, Thierry B , Coates PT . Interferon-Gama Modification of Mesenchymal Stem Cells: Implication of Autologous and Allogenic Mesenchymal Stem Cell Therapy in Allotransplantation. Stem Cells Rev 2014;10:351-75. 32. Nasef A, Mathieu N, Chapel A, Johanna F, Francois S, Mazurier C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G . Transplantation 2007; 84:231-7. 33. Bernardo ME, Locatelli F and E.Fibbe W. Mesenchymal stromal cells. Hematopoietic Stem Cells VII: Ann N Y Acad Sci 2009; 1176: 101-117. 34. Krampera M, Losmi L , Angeli R, Pasini A , Liotta F , Andreini A, et al . Role for interferon
gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-98.
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
35. Garcia
Gomes I ,Elvira G, Zapata AG, Lamana ML , Ramirez M ,Cstro JG, et al.
Mesenchymal stem cell : biological properties and clinical applications. Expert Opin Biol Ther 2010;10:1453-68. 36. Sato K, Ozaki K, Mori M,Ozawa K. Mesenchymal stromal cells for graft
versus
host
disease: basic aspects and clinical outcomes. J Clin Exp Hematop 2010;50:79-89. 37. Tolar J, Le Blank K, Keating A, Blazar BR . Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010; 28:1446-55. 38. Kenneth W , Liechty KW, Tippi C , Mackenzie TC, Shaaban AF,Antoneta Radu, et al. Human mesenchymal stem cells engraft and demonstrate site
specific differentiation after in utero transplantation in sheep. Nat Med 2000 ;6:1282-6. 39. Lama VN, Smith L, Badri L, Flint A , Murray S , Wang Z , et al.Evidence for tissue
resident mesenchymal stem cells in human adult lung from studies of transplanted allograft . J Clin Invest 2007 ; 117: 989 996. 40. Horwitz EM, Gordon PL , Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow
derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfect :Implications for cell therapy of bone . Proc Natl Acad Sci USA 2002 ;99:8932-7. 41. Kawada H, Fujita J, Kinjo K,Matsuzaki Y , Tsuma M, Miyatake H, et al.Nonhematopoietic mesenchymal stem cell can be mobilized and differentiate into cardiomyocyte after myocardial infarction . Blood 2004;104:3581-7. 42. Cheng Z, Ou L, Zhou X, Li F , Jia X , Zhang Y , et al.Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infracted myocardium improves cardiac performace. Mol Ther 2008;16:571-9. 43. Ko IK, Kim BG, Awadallah A,Mikulan J, Lin P, Letterio JJ, et al.Targeting improves MSC treatment of inflammatory bowel disease . Mol Ther 2010;18:1365-72. 44. Shi M , Li J, Liao L,Chen B, Li B , Chen L , et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment : role in homing efficiency in NOD/SCID mice. Haematologica 2007; 92:897-904. 45. Ren G, Zhao X, Zhang L, Zhang J, LHuillier A , Ling W , et al.Inflammatory cytokine- induced intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010;184:2321-8. 46. Studeny M, Marini FC, Champlin RE, Zompetta C , Fidler IJ, Andreeff M . Bone marrow
derived mesenchymal stem cells as vehicles for interferon beta delivery into tumors. Cancer Res 2002;62:3603-8. 47. Ren C, Kumar S , Chanda D, Kallman L, Chen J, Mountz JD, et al.Cancer gene therapy using mesenchymal stem cells expressing interferon- beta in a mouse prostate cancer lung metastasis model. Gene Ther 2008; 15:1446-53. 48. Seo SH , Kim KS, Park SH, Suh Y S , Kim S J , Jeun S-S , et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12
mediated antitumor activity . Gene Ther 2011;18:488-95. 49. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009 ;69:4134-42. 50. Ren C, Kumar S, Chanda D,Chen J, Mountz JD , Ponnazhagan S.Therapeutic potential of mesenchymal stem cells producing interferon-
in a mouse melanoma lung metastatasis model.Stem Cells 2008 ;26:2332-2338. 51. Schnabel LV, Lynch ME, van der Meulen MCH , Yeager A E , Kornatowski MA , Nixon AJ . Mesenchymal stem cells and insulin
Like growth factor -1 gene
enhanced
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficial tendons. J Orthop Res 2009; 27:1392-1398. 52. Tyndall A, Uccelli A. Miltipotent mesenchymal stromal cells for autoimmune diseases :teaching new dogs old tricks. Bone Marrow Transplant 2009;43:821-8. 53. Kim J, Hematti P. Mesenchymal stem cell- educated macrophages : a novel type of alternatively activated macrophages. Exp Hematol 2009;37:1445-53. 54. Kebriaei P, Isola L , Bachceci E, Holland K , Rowley S , McGuirk J , et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft
versus-host disease . Biol Blood Marrow Transplant 2009;15:804-11. 55. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008 ;371:1579-86. 56. Ciccocioppo R , Bernardo ME, Sgarella A, Maccario R , Avanzini MA ,Ubezio C , et al . Autologous bone marrow derived mesenchymal stromal cells in the treatment of fistulising Crohn s disease. Gut 2011;60:788-98. 57. Connick P, Kolappan M, Patani R, Scott MA , Crawley C, He XL , et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics : an open
label pre-test:post-test study with blinded outcome assessments. Trials 2011;12:62. 58. Hanmou O, Houkin K, Matsunaga T,Niitsu Y, Ishiai S , Onodera R , et al.Intravenous administration of auto serum expanded autologous mesenchymal stem cells in stroke. Brain 2011 ;134:1790-807. 59. Zhang D , Zhang L , Shi H , Chen X , Wan Y , Zhang H , et al. Suppresion of Peritoenal Tumorgenesis by Placenta-Derived Mesenchymal Stem Cells Expressing Endostatin on Colorectal Cancer.Int J Med Sci 2014; 11:870-879. 60. Serakinci N , Fahrioglu U, Christensen R . Mesenchymal stem cells ,cancer challenges and new directions. Eropean journal of Cancer 2014;50:1522-1530. 61. Farini A, Sitzia C , Erratico S , Mereqalli M , Torrente Y. Clinical Applications of Mesenchymal Stem Cells in Chronic Diseases.Stem cells Int 2014 ; 2014 : 306573,11pages. 62. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot Lj, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell - mediated breast cancer metastasis. Carcinogenesis 2011;32:477-87. 63. Karnoub AE, Dash AB, Vo AP,Sullivan A, Brooks MW , Bell GW, et al.Mesenchymal stem cell within tumor stroma promote breast cancer metastasis.Nature 2007;449-557-63. 64. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Scince 2005;307:57-62. 65. Gao J, Dennis JE, Muzic RF, Lundberg M,Caplan AI. The dynamic in vivo distribution of bone marrow derived mesenchymal stem cells after infusion. Cell Tissues Organs 2011;169:12-20. 66. Moniri MR, Dai L-J and Warnoc. The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Therapy 2014;21:12-23. 67. Liu J, Liu XF, Wan L, Li YP, Li SF, Zheng LY, et al. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesennchymal stem cells dervived from bone marrow of Banna Minipig inbred line. Transplant Proc 2004;36:3272-5. 68. Karimi MM , Adib M, Hashemi Beni B,Alipour R , Hassanzadeh A. Immonomodulatory Properties of Human Bone Marrow Mesenchymal Stem Cells on T Lymphocyte proliferation. Journal of Isfahan Medical School 2012; 29. [In Persian]
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
69. Kampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone Marrow inhibit the response of Naïve and memory antigen specific T cells to their cognate peptid. Blood 2003;101:3722-9. 70. Augella A , Tasso R, Negrimi SM , Amateis A, Indiveri F , Cancedda R , et al.Bone marrow mesenchymal stem cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005;35:1482-90.
Dow
nloa
ded
from
sjk
u.m
uk.a
c.ir
at 2
3:18
+03
30 o
n S
unda
y O
ctob
er 1
7th
2021
[
DO
I: 10
.221
02/2
0.3.
113
]
